Cargando…
Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region
BACKGROUND: Current guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) for patients with cancer who are at greater risk of febrile neutropenia (FN) while receiving chemotherapy. G-CSF biosimilars are available and represent a savings opportunity; however, their upt...
Autores principales: | Trotta, Francesco, Mayer, Flavia, Mecozzi, Alessandra, Amato, Laura, Addis, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380704/ https://www.ncbi.nlm.nih.gov/pubmed/28353170 http://dx.doi.org/10.1007/s40259-017-0214-9 |
Ejemplares similares
-
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023) -
Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009) -
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015) -
Tool for Guidance: Evidence-Based Recommendations for Managing Febrile Neutropenia
por: Ullmann, Andrew J.
Publicado: (2011) -
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
por: Trotta, Francesco, et al.
Publicado: (2017)